Cabot Corp (CBT) FinancialsCBTFinancialCabot Corp

Cabot Corp (CBT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reinforcement Materials, accounting for 61.0% of total sales, equivalent to $599.00M. Other significant revenue streams include Performance chemicals and Unallocated and Other. Understanding this composition is critical for investors evaluating how CBT navigates market cycles within the Specialty Chemicals industry.

Evaluating the bottom line, Cabot Corp maintains a gross margin of 19.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.79%, while the net margin is 1.43%. These profitability ratios, combined with a Return on Equity (ROE) of 11.89%, provide a clear picture of how effectively CBT converts its operational activities into shareholder value.

In the context of the broader market, CBT competes directly with industry leaders such as CE and BAK. With a market capitalization of $4.54B, it holds a significant position in the sector. When comparing efficiency, CBT's gross margin of 19.35% stands against CE's 21.04% and BAK's 24.48%. Such benchmarking helps identify whether Cabot Corp is trading at a premium or discount relative to its financial performance.

Cabot's revenue for Q3 was $982 million, a 6.4% increase year-over-year, but net income dropped drastically to $6 million, reflecting profitability issues. The gross margin has also decreased to 19.35% in Q3, down from 26.44% in Q3 of the previous year.